Noninvasive vaccine delivery systems need to incorporate an effective adjuvant, specially designed for triggering both mucosal and systemic immune responses.
The global market for Non-invasive Vaccine is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Non-invasive Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Non-invasive Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Non-invasive Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Non-invasive Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Non-invasive Vaccine players cover Merck, GSK, Sanofi, Lanzhou Institute and Serum Institute, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This latest report provides a deep insight into the global Non-invasive Vaccine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Non-invasive Vaccine market, with both quantitative and qualitative data, to help readers understand how the Non-invasive Vaccine market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in Units.
The study segments the Non-invasive Vaccine market and forecasts the market size by Type (Oral Vaccine and Nasal Spray Vaccine,), by Application (Public and Private.), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Nasal Spray Vaccine
Segmentation by application
Segmentation by region
Middle East & Africa
Major companies covered
Shanghai United Cell
Panacea Biotec Ltd
Chapter 1: Scope of Non-invasive Vaccine, Research Methodology, etc.
Chapter 2: Executive Summary, global Non-invasive Vaccine market size (sales and revenue) and CAGR, Non-invasive Vaccine market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Non-invasive Vaccine sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Non-invasive Vaccine sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Non-invasive Vaccine market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Merck, GSK, Sanofi, Lanzhou Institute, Serum Institute, Valneva, Shanghai United Cell, Bibcol and PaxVax, etc.
Chapter 14: Research Findings and Conclusion